COVID19 and Finding Effective Medical Therapies
This post introduces a column I wrote over at TheHeart.org | Medscape Cardiology — The good news is that most people infected with coronavirus don’t need a hospital or doctor. But some do. Some get very ill. The maddening thing is that doctors don’t have an effective treatment for the virus. There are no cures. The Worldmeter today shows nearly 5 million infections and more than 300,000 deaths. And no effective therapy. Excluding a possibly modest effect of Remdesivir, our care is supportive, which is medical jargon for giving simple things like oxygen, acetaminophen, IV fluids and letting the body do the rest. That sentence makes supportive care seem simple, but it is not so with COVID19. The virus can cause havoc in the body. Damage to the lungs (pneumonia) gets most of the attention, but other organs can be harmed. COVID19 and Clotting: One system in particular that can go haywire is the clotting system (medical term is coagulation). Many studies have shown that patients ill with COVID19 can have excess clotting. (It’s not well known, but our bodies do this elegant dance to keep the blood clotting factors and thinning factors in balance. Medical people call this equilibrium or homeostasis of the coagulation system.) We now have blood tests that give us a window, albeit a somewhat opaque one, onto the clotting system. Also imperfect is the observation that patients with COVID19 can clot off intravenous lines, or on a...
Publication date: Available online 3 July 2020Source: American Journal of OtolaryngologyAuthor(s): Ali Safavi Naeini, Mahboobeh Karimi-Galougahi, Nasim Raad, Jahangir Ghorbani, Ayeh Taraghi, Sara Haseli, Golfam Mehrparvar, Mehrdad Bakhshayeshkaram
Publication date: Available online 3 July 2020Source: Best Practice &Research Clinical AnaesthesiologyAuthor(s): Eleni Moka, Antonella Paladini, Martina Rekatsina, Ivan Urits, Omar Viswanath, Alan D. Kaye, Cheng Teng Yeam, Giustino Varrassi
Conclusions: Preoperative higher ALFF in the bilateral MCC and lower FC between the bilateral MCC and left calcarine were independently associated with the occurrence of DNR. The present fMRI study identified possible preoperative neuroimaging risk factors for DNR. This trial is registered with Chinese Clinical Trial Registry ChiCTR-DCD-15006096. PMID: 32617099 [PubMed - in process]
Abstract Recovery of motor function after stroke involves many biomarkers. This review attempts to identify the biomarker effects responsible for recovery of motor function following the use of Constraint-Induced Movement Therapy (CIMT) and discuss their implications for research and practice. From the studies reviewed, the biomarker effects identified include improved perfusion of motor areas and brain glucose metabolism; increased expression of proteins, namely, Brain-Derived Neurotrophic Factor (BDNF), Vascular Endothelial Growth Factor (VEGF), and Growth-Associated Protein 43 (GAP-43); and decreased level of G...
Publication date: Available online 4 July 2020Source: Molecular and Cellular ProbesAuthor(s): Raheleh Torabi, Reza Ranjbar, Mehrdad Halaji, Mohammad Heiat
Publication date: Available online 4 July 2020Source: Advances in Biological RegulationAuthor(s): Günther Schönrich, Martin J. Raftery, Yvonne Samstag
Publication date: 4 July 2020Source: New Scientist, Volume 247, Issue 3289Author(s): Adam Vaughan
Publication date: 4 July 2020Source: New Scientist, Volume 247, Issue 3289Author(s): Clare Wilson
Publication date: 4 July 2020Source: New Scientist, Volume 247, Issue 3289Author(s): Michael Le Page
Publication date: 4 July 2020Source: New Scientist, Volume 247, Issue 3289Author(s): Michael Marshall